PURPOSE: Of the 737 patients with aggressive lymphoma who were treated with the LNH-84 regimen, 244 with progressive disease after complete remission or partial response were analyzed retrospectively to determine the influence of intensive chemotherapy with bone marrow transplantation (BMT) on survival. PATIENTS AND METHODS: Forty-four patients were treated with salvage chemotherapy, followed by autologous bone marrow transplantation (ABMT) in 40 and allogeneic BMT in four. The other 200 patients were treated with chemotherapy only. RESULTS: Salvage treatment produced an objective response in 57% of the patients; 23% achieved a second complete remission. Median overall survival was longer for patients who were treated with ABMT than for those who were treated with chemotherapy only (12.4 v 6.7 months), as was median freedom from progression (FFP) survival (7.7 v 4 months). In multiparametric analysis, ABMT and normal initial lactic dehydrogenase (LDH) level were the primary parameters associated with longer survival. This is also true when (1) only patients younger than 60 years of age, (2) only patients who responded to salvage regimen, or (3) only patients with both conditions were included in the analysis. Patients who were not transplanted had a 1.69 to 2.26 relative risk of dying from their disease compared with those who were treated with intensive chemotherapy plus ABMT. CONCLUSION: This study produced more evidence of the favorable impact of intensive chemotherapy with bone marrow rescue on survival in lymphoma patients who had relapsed.
PURPOSE: Of the 737 patients with aggressive lymphoma who were treated with the LNH-84 regimen, 244 with progressive disease after complete remission or partial response were analyzed retrospectively to determine the influence of intensive chemotherapy with bone marrow transplantation (BMT) on survival. PATIENTS AND METHODS: Forty-four patients were treated with salvage chemotherapy, followed by autologous bone marrow transplantation (ABMT) in 40 and allogeneic BMT in four. The other 200 patients were treated with chemotherapy only. RESULTS: Salvage treatment produced an objective response in 57% of the patients; 23% achieved a second complete remission. Median overall survival was longer for patients who were treated with ABMT than for those who were treated with chemotherapy only (12.4 v 6.7 months), as was median freedom from progression (FFP) survival (7.7 v 4 months). In multiparametric analysis, ABMT and normal initial lactic dehydrogenase (LDH) level were the primary parameters associated with longer survival. This is also true when (1) only patients younger than 60 years of age, (2) only patients who responded to salvage regimen, or (3) only patients with both conditions were included in the analysis. Patients who were not transplanted had a 1.69 to 2.26 relative risk of dying from their disease compared with those who were treated with intensive chemotherapy plus ABMT. CONCLUSION: This study produced more evidence of the favorable impact of intensive chemotherapy with bone marrow rescue on survival in lymphomapatients who had relapsed.
Authors: L G Lum; A Thakur; C Pray; N Kouttab; M Abedi; A Deol; W M Colaiace; R Rathore Journal: Bone Marrow Transplant Date: 2013-09-23 Impact factor: 5.483
Authors: Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass Journal: J Clin Oncol Date: 2012-10-22 Impact factor: 44.544
Authors: Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn Journal: Biol Blood Marrow Transplant Date: 2013-03-22 Impact factor: 5.742
Authors: Nadia Sadanandan; Alex Shear; Beverly Brooks; Madeline Saft; Dorothy Anne Galang Cabantan; Chase Kingsbury; Henry Zhang; Stefan Anthony; Zhen-Jie Wang; Felipe Esparza Salazar; Alma R Lezama Toledo; Germán Rivera Monroy; Joaquin Vega Gonzales-Portillo; Alexa Moscatello; Jea-Young Lee; Cesario V Borlongan Journal: Front Mol Neurosci Date: 2021-11-24 Impact factor: 5.639